BMEA Quote, Financials, Valuation and Earnings

IGM Biosciences has a net margin of -- compared to Biomea Fusion's net margin of -8894.9%. Biomea Fusion's return on equity of -- beat IGM Biosciences's return on equity of -159.45%.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 1228.57%. On the other hand IGM Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 56.25%. Given that Biomea Fusion has higher upside potential than IGM Biosciences, analysts believe Biomea Fusion is more attractive than IGM Biosciences.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.126%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than IGM Biosciences quarterly revenues of $412K. Biomea Fusion's net income of -$32.8M is higher than IGM Biosciences's net income of -$36.6M. Notably, Biomea Fusion's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 27.11x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Biomea Fusion's net margin of 32.59%. Biomea Fusion's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 1228.57%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 37.99%. Given that Biomea Fusion has higher upside potential than Eli Lilly and, analysts believe Biomea Fusion is more attractive than Eli Lilly and.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Biomea Fusion pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biomea Fusion quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biomea Fusion's net income of -$32.8M is lower than Eli Lilly and's net income of $4.4B. Notably, Biomea Fusion's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 62.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 14.70x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Biomea Fusion's net margin of -49.65%. Biomea Fusion's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 1228.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Biomea Fusion has higher upside potential than NovaBay Pharmaceuticals, analysts believe Biomea Fusion is more attractive than NovaBay Pharmaceuticals.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Biomea Fusion's net income of -$32.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Biomea Fusion's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Biomea Fusion's net margin of -2357.27%. Biomea Fusion's return on equity of -- beat Palatin Technologies's return on equity of --.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 1228.57%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Biomea Fusion, analysts believe Palatin Technologies is more attractive than Biomea Fusion.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Biomea Fusion's net income of -$32.8M is lower than Palatin Technologies's net income of -$2.4M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.